Acurx Pharmaceuticals, Inc. (ACXP) |
|
3.54 0.29 (8.92%)
|
03-24 16:00 |
|
Open: |
3.31 |
Pre. Close: |
3.25 |
|
High:
|
3.55 |
Low:
|
3.28 |
|
Volume:
|
2,887 |
Market Cap:
|
41(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:46 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 4.54 One year: 5.3 |
| Support: |
Support1: 3.33 Support2: 3 |
| Resistance: |
Resistance1: 3.89 Resistance2: 4.54 |
| Pivot: |
3.37  |
| Moving Average: |
MA(5): 3.24 MA(20): 3.38
MA(100): 3.53 MA(250): 3.5 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 38.2 %D(3): 25 |
| RSI: |
RSI(14): 54.4 |
| 52-week: |
High: 4.84 Low: 2.32 |
| Average Vol(K): |
3-Month: 35 (K) 10-Days: 32 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACXP ] has closed below upper band by 26.6%. Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.55 - 3.56 |
3.56 - 3.57 |
|
Low:
|
3.25 - 3.26 |
3.26 - 3.28 |
|
Close:
|
3.51 - 3.54 |
3.54 - 3.56 |
|
Company Description |
|
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. |
Headline News |
Thu, 23 Mar 2023
New to The Street Signs Acurx Pharmaceuticals, Inc. to Additional Six-Month Media Contract with Iconic Billboard Ads and Commercial Support - Yahoo Finance
Fri, 17 Mar 2023
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2022 Earnings Call Transcript - Yahoo Finance
Mon, 06 Mar 2023
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year ... - PR Newswire
Thu, 02 Mar 2023
Factbox-Elon Musk's missed deadlines for FDA approval of Neuralink brain-chip trials - Yahoo News
Thu, 16 Feb 2023
Tenon Medical Inc (TNON) has fallen 12.39% Thursday In Premarket Trading - InvestorsObserver
Tue, 14 Feb 2023
Acurx is Setting a High Bar for New Treatments in C. diff - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
12 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
21.1 (%) |
|
% Held by Institutions
|
11.9 (%) |
|
Shares Short
|
25 (K) |
|
Shares Short P.Month
|
21 (K) |
Stock Financials |
|
EPS
|
-0.99 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.62 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-66.8 |
|
Return on Equity (ttm)
|
-122.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-8 (M) |
|
Levered Free Cash Flow
|
-3 (M) |
Stock Valuations |
|
PE Ratio
|
-3.62 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
5.61 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-5.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
